PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $58.10 million. The enterprise value is $68.87 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 6.32 million shares outstanding. The number of shares has decreased by -69.15% in one year.
| Current Share Class | 6.32M |
| Shares Outstanding | 6.32M |
| Shares Change (YoY) | -69.15% |
| Shares Change (QoQ) | +24.60% |
| Owned by Insiders (%) | 23.40% |
| Owned by Institutions (%) | 3.32% |
| Float | 3.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 809.43 |
| Forward PS | 114.99 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 6.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 969.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.17, with a Debt / Equity ratio of 0.60.
| Current Ratio | 0.17 |
| Quick Ratio | 0.13 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,038.38 |
Financial Efficiency
Return on equity (ROE) is -32.34% and return on invested capital (ROIC) is -45.07%.
| Return on Equity (ROE) | -32.34% |
| Return on Assets (ROA) | -39.24% |
| Return on Invested Capital (ROIC) | -45.07% |
| Return on Capital Employed (ROCE) | -90.95% |
| Weighted Average Cost of Capital (WACC) | 7.11% |
| Revenue Per Employee | $1,732 |
| Profits Per Employee | -$92,049 |
| Employee Count | 41 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.39% in the last 52 weeks. The beta is 0.81, so PAVmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -54.39% |
| 50-Day Moving Average | 10.00 |
| 200-Day Moving Average | 11.91 |
| Relative Strength Index (RSI) | 44.15 |
| Average Volume (20 Days) | 12,811 |
Short Selling Information
The latest short interest is 23,477, so 0.37% of the outstanding shares have been sold short.
| Short Interest | 23,477 |
| Short Previous Month | 23,246 |
| Short % of Shares Out | 0.37% |
| Short % of Float | 0.60% |
| Short Ratio (days to cover) | 0.58 |
Income Statement
In the last 12 months, PAVmed had revenue of $71,000 and -$3.77 million in losses. Loss per share was -$5.63.
| Revenue | 71,000 |
| Gross Profit | -147,000 |
| Operating Income | -21.81M |
| Pretax Income | -2.47M |
| Net Income | -3.77M |
| EBITDA | -21.70M |
| EBIT | -21.81M |
| Loss Per Share | -$5.63 |
Full Income StatementBalance Sheet
The company has $1.95 million in cash and $13.35 million in debt, with a net cash position of -$11.40 million or -$1.80 per share.
| Cash & Cash Equivalents | 1.95M |
| Total Debt | 13.35M |
| Net Cash | -11.40M |
| Net Cash Per Share | -$1.80 |
| Equity (Book Value) | 22.30M |
| Book Value Per Share | 10.01 |
| Working Capital | -12.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.21 million and capital expenditures -$31,000, giving a free cash flow of -$5.24 million.
| Operating Cash Flow | -5.21M |
| Capital Expenditures | -31,000 |
| Depreciation & Amortization | 105,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -5.24M |
| FCF Per Share | -$0.83 |
Full Cash Flow StatementMargins
Gross margin is -207.04%, with operating and profit margins of -30,712.68% and 564.79%.
| Gross Margin | -207.04% |
| Operating Margin | -30,712.68% |
| Pretax Margin | -3,477.46% |
| Profit Margin | 564.79% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 69.15% |
| Shareholder Yield | 69.15% |
| Earnings Yield | -6.57% |
| FCF Yield | -9.11% |
Analyst Forecast
The average price target for PAVmed is $65.00, which is 606.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $65.00 |
| Price Target Difference | 606.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
PAVmed has an Altman Z-Score of -11.21 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.21 |
| Piotroski F-Score | 1 |
